Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 277 No 7429 p656
2 December 2006

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Health and social care regulation to merge

Plans to merge the Healthcare Commission and the Commission for Social Care Inspection have been put out for public consultation (PDF 1MB) by the Department of Health. The new inspectorate will also take over the role of the Mental Health Act Commission.

The new commission will be responsible for ensuring the safety and quality of all publicly and privately funded health care and adult social care and for assessing performance. It will share responsibility for promoting choice and competition with the Office of Fair Trading and will help strategic health authorities monitor primary care trusts.

Sir Ian Kennedy, chairman of the Healthcare Commission, said that the proposals will ensure that regulation works in tandem with other changes in health and social care to promote better outcomes.

The new care regulator will be expected to register all public and private providers of health and adult social care and to measure them against a single set of national standards.

Sir Ian said that this will give patients a single assurance on safety and quality regardless of where they go for treatment. He added: “Where there are serious doubts about the safety of patients, the move would give the regulator powers to withdraw a provider’s right to provide NHS services.”

The consultation closes on 28 February 2007.

Stronger regulation A better regulatory system is needed for the emerging NHS market, according to the King’s Fund. On the day that consultation started on plans to merge health and social care regulation, a King’s Fund report called for stronger regulation to monitor and enforce the right competitive relationship between health care providers and to ensure an effective way of dealing with hospital failures. King’s Fund chief executive Niall Dickson added: “We need to balance the danger of over-regulation, which will stifle innovation, and an unbridled market, which could deliver chaos and inequity.”

Back to Top


©The Pharmaceutical Journal